E-ISSN: 2619-9467

Contents    Cover    Publication Date: 03 Nov 2021
Year 2021 - Volume 31 - Issue 3

Open Access

Peer Reviewed

206 Viewed130 Downloaded

The Effect of Estrogen and Progesterone Receptor Status on the Prognosis of Endometrioid Type Endometrial Cancer: Retrospective Study

Full Text PDF  
JCOG. 2021;31(3):77-83
DOI: 10.5336/jcog.2021-81692
Article Language: EN
Copyright Ⓒ 2020 by Türkiye Klinikleri. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Objective: Endometrioid-type endometrial cancer (EC) is the most common histological type of EC, and generally has good survival if diagnosed during the early stages. While tumour grade, stage and lymph node invasion are known to affect survival in these patients, the prognostic significance of steroid receptor status remains unclear. The present study aimed to determine the effect of estrogen and progesterone receptor (ER and PR, respectively) status and its relationship with other prognostic factors in endometrioid-type EC. Material and Methods: Data from 152 patients who underwent surgery at the same centre between 2009 and 2019 were retrospectively evaluated. Histological characteristics of tumours were determined using the original pathology reports, and stage, grade and lymph node involvement of tumours were compared with ER and PR status. The relationship between ER and PR status and preoperative serum cancer antigen 125 and albumin levels were also investigated. Results: When the results of our study were examined, it was revealed that 114 patients had Grade I tumor and 118 had International Federation of Gynecology and Obstetrics Stage I tumor and 34 patients had ER and PR negativity. In our study, a dependence was found between both ER and PR status and pelvic lymph node involvement. It was found that the possibility of pelvic lymph node involvement increases in both hormone receptor negativity. Conclusion: This study reports that the patients with pelvic lymph node involvement, which is a prognostic factor in EC, may experience more frequent ER and PR negativity. However, its effects on survival remain unclear.
  1. Bray F, Ferlay J, Soerjomataram I,Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidenceand mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin.2018;68(6):394-424. Erratum in: CA Cancer J Clin. 2020;70(4): 313. [Crossref]  [PubMed] 
  2. Bokhman JV. Two pathogenetic typesof endometrial carcinoma. Gynecol Oncol. 1983; 15(1):10-7. [Crossref]  [PubMed] 
  3. Kurman RJ, Carcangiu ML, Herrington CS. WHO Classification of Tumours ofFemale Reproductive Organs. 4th ed. Lyon: International Agency for Research on Cancer; 2014.
  4. Lax SF. Pathology of endometrialcarcinoma. In: Ellenson LH, ed. Molecular Genetics of Endometrial Carcinoma. 1st ed. Cham:Springer; 2017. p.75-96. [Crossref] [PubMed] 
  5. Amant F, Moerman P, Neven P,Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet. 2005;366(9484):491-505. [Crossref]  [PubMed] 
  6. Kosary CL. FIGO stage, histology,histologic grade, age and race as prognostic factors in determining survival for cancers ofthe female gynecological system: an analysis of 1973-87 SEER cases of cancers of theendometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol. 1994;10(1):31-46. [Crossref] [PubMed] 
  7. Schink JC, Rademaker AW, MillerDS, Lurain JR. Tumor size in endometrial cancer. Cancer. 1991;67(11):2791-4. [Crossref]  [PubMed] 
  8. Seebacher V, Grimm C, ReinthallerA, Heinze G, Tempfer C, Hefler L, et al. The value of serum albumin as a novel independentmarker for prognosis in patients with endometrial cancer. Eur J Obstet Gynecol Reprod Biol.2013;171(1):101-6. [Crossref]  [PubMed] 
  9. Salvesen HB, Haldorsen IS, TrovikJ. Markers for individualised therapy in endometrial carcinoma. Lancet Oncol.2012;13(8):e353-61. [Crossref]  [PubMed] 
  10. Budak E, Solakoglu Kahraman D,Budak A, Yanarateş A, Inan AH, Kanmaz AG, et al. The prognostic significance of serum CA125levels with ER, PR, P53 and Ki-67 expression in endometrial carcinomas. Ginekol Pol.2019;90(12):675-83. [Crossref]  [PubMed] 
  11. Liu R, Dong JT, Chen C. Role ofKLF5 in hormonal signaling and breast cancer development. Vitam Horm. 2013;93:213-25. [Crossref] [PubMed] 
  12. Ito K, Utsunomiya H, Yaegashi N,Sasano H. Biological roles of estrogen and progesterone in human endometrial carcinoma--newdevelopments in potential endocrine therapy for endometrial cancer. Endocr J. 2007;54(5):667-79. [Crossref]  [PubMed] 
  13. Zhao D, Zhang F, Zhang W, He J,Zhao Y, Sun J. Prognostic role of hormone receptors in ovarian cancer: a systematic reviewand meta-analysis. Int J Gynecol Cancer. 2013;23(1):25-33. [Crossref]  [PubMed] 
  14. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al;American Society of Clinical Oncology; College of American Pathologists. American Society ofClinical Oncology/College of American Pathologists guideline recommendations forimmunohistochemical testing of estrogen and progesterone receptors in breast cancer(unabridged version). Arch Pathol Lab Med. 2010;134(7):e48-72. [PubMed] 
  15. Osborne CK, Yochmowitz MG, KnightWA 3rd, McGuire WL. The value of estrogen and progesterone receptors in the treatment ofbreast cancer. Cancer. 1980;46(12 Suppl):2884-8. [Crossref] 
  16. Burton JL, Wells M. Recentadvances in the histopathology and molecular pathology of carcinoma of the endometrium.Histopathology. 1998;33(4):297-303. [Crossref]  [PubMed] 
  17. Kounelis S, Kapranos N, Kouri E,Coppola D, Papadaki H, Jones MW. Immunohistochemical profile of endometrial adenocarcinoma:a study of 61 cases and review of the literature. Mod Pathol. 2000;13(4):379-88. [Crossref] [PubMed] 
  18. Gul AE, Keser SH, Barisik NO,Kandemir NO, Cakir C, Sensu S, et al. The relationship of cerb B 2 expression with estrogenreceptor and progesterone receptor and prognostic parameters in endometrial carcinomas.Diagn Pathol. 2010;5:13. [Crossref]  [PubMed]  [PMC] 
  19. Zhang Y, Zhao D, Gong C, Zhang F,He J, Zhang W, et al. Prognostic role of hormone receptors in endometrial cancer: asystematic review and meta-analysis. World J Surg Oncol. 2015;13:208. d [Crossref]  [PubMed]  [PMC] 
  20. Creasman WT. Prognosticsignificance of hormone receptors in endometrial cancer. Cancer. 1993;71(4 Suppl):1467-70. [Crossref]  [PubMed] 
  21. Reijnen C, Visser NC, Kasius JC,Boll D, Geomini PM, Ngo H, et al. Improved preoperative risk stratification with CA-125 inlow-grade endometrial cancer: a multicenter prospective cohort study. J Gynecol Oncol.2019;30(5): e70. [Crossref]  [PubMed]  [PMC] 
  22. Seebacher V, Grimm C, ReinthallerA, Heinze G, Tempfer C, Hefler L, et al. The value of serum albumin as a novel independentmarker for prognosis in patients with endometrial cancer. Eur J Obstet Gynecol Reprod Biol.2013;171(1):101-6. [Crossref]  [PubMed]